

AREA DRUG & THERAPEUTICS COMMITTEE

ANNUAL REPORT

APRIL 2018 – MARCH 2019

Page 1 of 8

CONTENTS

Introduction	Page 3
Remit	Page 3
Structure and organisation	Page 4
ADTC Membership	Page 4
Applications for Approval	Page 5
Schedule of Business April 2018 – March 2019	Page 5 - 7
Attendance of Members	Page 8

Introduction:

The Area Drug and Therapeutics Committee is a standing committee of NHS Borders Board. Patient Safety is at the heart of all considerations and decisions made by the ADTC and its sub-committees.

Remit

- 1. To advise and support the strategic direction of all aspects of medicines governance and usage in all care settings ensuring inclusion within wider strategic planning carried out by the NHS Board.
- 2. To ensure multi-stakeholder engagement and joint working on all medicine related issues within all care settings, including social care settings.
- 3. To develop and monitor Borders-wide prescribing policies and treatment guidelines to optimise safe and cost effective use of medicines.
- 4. To advise, monitor and co-ordinate the development and approval of policies and procedures relating to prescribing, administration and the safe and secure handling of medicines and support NHS Borders Board in meeting its statutory responsibilities in relation to medicines and prescribing.
- 5. To support NHS Borders Board in the delivery of a comprehensive approach to national policy regarding medicines, linking with Regional and National groups.
- 6. To oversee the systems for safer medicines use, including SPSP Safer Medicines Group / Medicines Reconciliation
- 7. To respond to national directives and initiatives related to the use of medicines, in particular that issued by the Scottish Medicines Consortium, Scottish Intercollegiate Guidelines Network (SIGN), National Institute for Healthcare and Clinical Excellence (NICE),.
- 8. To oversee the system for evaluation of new therapeutic developments and effectively manage their introduction into routine use in NHS Borders. The committee will consider new medicine applications where a decision is required before the next Formulary Committee meeting.
- 9. To ensure systems are in place for the dissemination of information and advice to professional staff, patients and public promoting safe, efficient and cost-effective use of medicines taking into account current evidence and best practice.
- 10.To promote seamless care for patients transferring between community and hospital care.
- 11.To ensure equitable access to medicines through non-medical prescribing and patient group directions.
- 12. The ADTC provides advice to NHS Borders, and supports the work of the Area Medical Committee, Area Pharmaceutical Committee, Area Nursing and Midwifery Committee and other relevant profession committees.

Structure and Organisation:

Standing sub committees/groups reporting to the Area Drug and Therapeutics Committee (ADTC) are:-

- Anti-Coagulant Committee
- Antimicrobial Team
- Borders Formulary Committee (BFC)
- Individual Patient Treatment Request (IPTR) Panel
- IV Therapy Group
- Non Medical Prescribing (NMP) steering group
- Tissue Viability Group
- Wound Formulary Group

Minutes from recent meetings of these groups are included in the ADTC agenda.

The full ADTC meets on alternative months with the BFC.

ADTC MEMBERSHIP: 2018/19 – NHS BORDERS

Mrs Alison Wilson, Chair (Non-executive Board Member; Chair of Area Clinical Forum)

Mr Keith Allan, Vice Chair – Public Health Consultant

Dr Rachel Stewart, Consultant, BGH

Dr Elliot Longworth, General Practitioner, West Linton Medical Practice

Dr Nicola Henderson, General Practitioner, Coldstream Medical Practice

Dr Edward James, Consultant Microbiologist

Mrs Catherine Scott, Senior Pharmacist clinical and quality care

Ms Liz Leitch, Formulary Pharmacist

Mr Keith Maclure, Senior Pharmacist medicines utilisation and planning

Mr Adrian Mackenzie, Lead Pharmacist – Community Pharmacy

Mr Mark Clark, Lead Nurse Non-Medical Prescribing and Medicines Governance

Mr Andrew Leitch, Lay member (nominated by the Patient & Public Forum)

Mrs Kate Warner, Committee Secretariat (PA to Director of Pharmacy)

Applications for Approval April 2018 - March 2019

	NEW MEDICINE APPLICATIONS BROUGHT TO ADTO	C MEETI	NG OF 9	9 th MAY 201	18	
NMA	Indication		Speciality		ADTC	
					De	ecision
Flucytosine	Treatment of fungal infection as adjunct to sta	eatment of fungal infection as adjunct to standard		biology	Ca	ategory B
(Ancotil)	therapy.				un	der direction
					of	Microbiologist
	NEW MEDICINE APPLICATIONS BROUGHT TO ADTC	MEETI	NG OF 1	1 th JULY 20	18	
NMA	Indication		Specia	ality	ADT	С
				2	Dec	ision
Promethiazine	Rapid tranquilisation in patients who IM lorazepa	am is	Menta	al Health	Unlic	censed/Off-
(Phenergan)	not appropriate e.g. benzodiazepine tolerance				Lab	el – Green
, U ,	benzodiazepine addiction					
benzodiazepine addiction Image: Constraint of the second sec						
NMA	Indication		Speciality			ADTC
				1 5		Decision
No applications a	t this meeting.					
NEV	/ MEDICINE APPLICATIONS BROUGHT TO ADTC ME	ETING	OF 14 th I	NOVEMBER	2018	
NMA	Indication		Special	ity		ADTC
				-		Decision
No applications a	t this meeting					
NE	W MEDICINE APPLICATIONS BROUGHT TO ADTC N	/IEETINC	G OF 9th	JANUARY 2	2019	
	Indication			Speciality	y	ADTC
						Decision
No applications a	t this meeting					
N	EW MEDICINE APPLICATIONS BROUGHT TO ADTC N	VIEETIN	G OF 13	^h MARCH 2	2019	
NMA	Indication	Specia	ality	ADT	Ċ	
			5	Dec	sision	
Dupilumab	Treatment of moderate to severe atopic	f moderate to severe atopic Dermatology Category B				
(Dupixent)	dermatitis in adult patient who are		0,		0)	
	candidates for systemic therapy.					

Schedule of business considered - April 2018 - March 2019

Meeting	Title of Business Discussed
	Matters Arising: None.
	Patient & Medicine Safety: update on meeting including colleagues from HIS
	providing useful feedback to the group; work continues in MAU and Ward 7 (100%
	medicines reconciliation); nurse led project to review missed doses.
	Clinical Policies, Procedures and Guidelines: NHS Borders IV Fluid Guidance; Guidance
	for Treatment of Electrolyte Deficiency; Mental Health Depot Guidelines and High
	Dose Guidelines; Suspicious Substances Policy; Policy for Management of Controlled
09.05.2018	Drugs in Secondary Care; Valproate Guidelines; Bevacizumab prescribing; PCS Tier
	Two Policy (new); Free of Charge Schemes; ADTC Annual Review 2017-18.
	For Information and Noting: Single National Formulary update; NHS Forth Valley's
	HEPMA implementation; Quality Prescribing Strategies for Pain, Respiratory and
	Diabetes; minutes from Borders Formulary Committee, Antimicrobial Team Meeting; IV
	Therapy Group, Tissue Viability Group; Medicines Reconciliation Safety Group and NHS
	Lothian ADTC meetings.
	AOCB: IV Immunoglobulin shortages; Electronic Drug Cabinets business case.

Meeting	Title of Business Discussed			
	Matters Arising: Freestyle Libre flash glucose monitoring update.			
	Presentation: Single National Formulary - Alpana Mair (Head of Effective Prescribing and Therapeutics), Steven Fenton (SNF Project Manager) and Anne Gilchrist (Formulary Pharmacist).			
	Patient & Medicine Safety: work continues MAU, Ward 7 and Ward 9.			
	Clinical Policies, Procedures and Guidelines: Policy for the Use of Licensed Medication			
11.07.2018 or Preparation and Use of Off-Label and Unlicensed Prescribing; NICE MTA				
	changes; update to Guideline for prescribing Vitamin D and Calcium.			
	For Information and Noting: minutes from Borders Formulary Committee, Antimicrobial			
	Team, Anticoagulant Committee, IV Therapy Group, Tissue Viability Group; Wound			
	Formulary Group, Medicines Reconciliation Safety Group and NHS Lothian ADTC			
	meetings.			
	AOCB: Midazolam for Control of Seizures; feedback and update to Medicines Chart.			

Meeting	Title of Business Discussed
	Matters Arising: None.
	Patient & Medicine Safety: Pharmacy completing audits for Ward 7 and 9 and
	discussing with pre-assessment.
	Clinical Policies, Procedures and Guidelines: Infant Milk prescribing recommendations;
	Non Medical Prescribing Budget Code changes; Drugs & Therapeutic Industry
	Engagement Policy update; Wound Formulary updates.
12.09.2018	For Information and Noting: Clinical documents update process; Shared Care update
	in the Treatment of Attention Deficit/Hyperactivity Disorders; Code of Practice for
	Control of Medicines update; SMC new ultra-orphan definition and pathway;
	Potassium Chloride IV Drug Monograph; minutes from Borders Formulary Committee,
	Antimicrobial Team, IV Therapy Group, Tissue Viability Group, Medicines Reconciliation
	Safety Group and NHS Lothian ADTC meetings.
	AOCB: Funding for Electronic Cabinets

Meeting	Title of Business Discussed
	Matters Arising: None
	Presentation: NHS Borders in a Changing World – Dr Cliff Sharp, Medical Director NHS
	Borders
	Patient & Medicine Safety: Quality improvement work in MAU
	Clinical Policies, Procedures and Guidelines: Rapid Tranquilisation in the Adult Inpatient
	Mental Health Unit; PACS Tier Two paperwork updates; Code of Practice for Control of
14.11.2018	Medicines update.
	For Information and Noting: ADTC Chairs and Professional Secretaries WebEx;
	Cannabis based products for medicinal use from CMO; SBAR Bevacizumab for
	Ophthalmic Use update; MHRA Safety Update; minutes from Borders Formulary
	Committee, Antimicrobial Team, IV Therapy Group, Tissue Viability Group and NHS
	Lothian ADTC meetings.
	AOCB: Transdermal fentanyl patches; Enoxaparin; nomination of Dr P Neary to SMC.

Meeting	Title of Business Discussed			
	Matters Arising: None			
	Presentation: Work of Scottish Medicines Consortium - Dr MacDonald, Chair of Scottish			
	Medicines Consortium and Dr Mark MacGregor, Consultant Physician and			
	Nephrologist, NHS Ayrshire & Arran and SMC Executive member			
Patient & Medicine Safety: No updates				
09.01.2019	Clinical Policies, Procedures and Guidelines: Policy for Medicines Management			
	Support by Healthcare Workers in Hospital to Home Service; new Band 4 Health Care			
	Assistant Roles; Controlled Drug Receipting and Checking staff changes to policies;			
	Code of Practice for Control of Medicines staff changes; NMC Standards update;			
	N/Saline flushes after IV cannulation; Antimicrobial Team Terms of Reference; NHS			
	Scotland Approach to Pre-Health Technology Assessment Free of Charge Pricing			

Schemes; NHS Borders Policy for Processing Requests to prescribe Unlicensed Medicines, Off-Label Medicines, Non Formulary Requests or PACS Tier Two Requests update to policy.
For Information and Noting: Bevacizumab use in age-related macular degeneration; Supplementary information on Cannabis Based Products for Medicinal Use; Yellow Card Centre Scotland Annual Report 2017-18 and e-reporting through Vision; minutes from Borders Formulary Committee, Antimicrobial Team; Anticoagulant Committee; IV Therapy Group; Tissue Viability Group; Wound Formulary Group; Medicines Reconciliation Group and NHS Lothian ADTC meetings.
AOCB: NFR Atovaquone.

Meeting	Title of Business Discussed
	Matters Arising: Process for qualification and support of HCA roles – Band 4.
	Patient & Medicine Safety: Medicines Reconciliation Safety Group; ongoing work in
	Ward 7, 9 and MAU.
	Non Formulary Requests discussed: Unpegylated alpha interferon; Mexilitine;
	Budesonide; Mistletoe; Cannabidiol; Synacthaen Depot.
	Clinical Policies, Procedures and Guidelines: Competencies for Medicine
	Management Assistant Practitioners (Theatre) Band 4; New Medicines Application
	Form update; Drugs & Therapeutic Industry Engagement Policy update and
	communications; Rapid Tranquilisation in the Older Adult Inpatient Mental Health Unit
	(over 65) policy; Shared Care Protocols identifying and updating; Erythropoiesis
13.03.2019	Stimulating Agents (ESAs) update; Formulary amendment Herpes zoster and Varicella
	zoster vaccination.
	For Information and Noting: Bevacizumab update; NHS Scotland Pre-Health
	Technology Assessment Free-of-Charge Pricing Arrangments guidance; Access to
	Medicines for extremely rare conditions via NHS Scotland ultra-orphan pathway;
	Medicines Update from Health Improvement Scotland; NHS Borders Hospital
	Antimicrobial Point Prevalence Survey 2018; minute from Borders Formulary
	Committee, Antimicrobial Team, Anticoagulant Committee, Tissue Viability Group,
	Wound Formulary Group and IV Therapy Group.
	AOCB: SBAR and Internal Audit – Homecare; thanks to Catherine Scott, Senior Clinical
	Pharmacist who is retiring end March 2019.

Attendance for ADTC during 2018/19

Dates of Meetings						
	09.05.18	11.07.18	12.09.18	14.11.18	09.01.19	13.03.19
Name						
Mrs Alison Wilson	✓	✓	✓	✓	✓	✓
Mr Keith Allan	-	✓	-	✓	-	-
Dr Rachel Stewart	✓	✓	-	-	✓	-
Dr Nicola Henderson	✓	✓	✓	-	✓	✓
Dr Edward James	✓	✓	✓	✓	✓	✓
Mrs Catherine Scott	✓	✓	✓	✓	✓	✓
Ms Liz Leitch	✓	\checkmark	-	-	✓	✓
Mr Keith Maclure	\checkmark	\checkmark	-	\checkmark	✓	✓
Mr Adrian Mackenzie	✓	-	-	✓	✓	✓
Mr Mark Clark	✓	-	✓	✓	✓	-
Dr Subodh Subodh	-	-	-	-	-	✓
Mr Andrew Leitch	✓	✓	✓	-	✓	✓
Mrs Kate Warner (Minute)	✓	✓	~	✓	✓	~
Invited Guests:						
Marianne Ward	✓					
Lesley Flannigan	✓					
Kyna Platts	✓					
Alpana Mair		✓				
Steven Fenton		✓				
Anne Gilchrist		✓				
Dr Cliff Sharp		✓				
June Smyth		✓				
Lynne Cairns			✓			
Dr Cliff Sharp				✓		
Kyna Platts				✓		
Paulina Mlawa				✓		
Dr Paul Neary					✓	
Dr MacDonald SMC					✓	
Dr MacGregor SMC					✓	
Alison Patterson					✓	
Nate Richardson-Read						✓